Stomach Cancer PDX

Patient Derived Xenograft (PDX) Mouse Models and Efficacy Services
Leukemias PDXStomach Cancer PDXPancreatic Cancer PDXOvarian Cancer PDXLung cancer PDXColorectal Cancer PDXBreast Cancer PDXBladder Cancer PDX
Humanized Immune Checkpoint Mouse Models and Efficacy Services
Anti-PD1 Drug-resistant Tumor ModelsIn Vivo Efficacy Studies Using TIGIT Humanized ModelsPDL1 Humanized Mouse ModelPD1 Humanized Mouse ModelsOX40 Humanized Mouse ModelsIn vivo Efficacy Test in LAG3 Humanized Mouse ModelsIn vivo Efficacy Test in GITR Humanized Mouse ModelCTLA4 Humanized Mouse ModelsIn vivo Efficacy Test in CD137 Humanized Models

Stomach cancer, also known as gastric cancer, is the fifth-leading type of cancer and the third-leading cause of death from cancer, making up 9% of global mortality rate. The major treatment for advanced stomach cancer is a combination of neoadjuvant radiotherapy, targeted therapy, and immunotherapy, using classical targets such as PD-1/PD-L1, HER-2, and VEGF/VEGFR, as well as the novel target Claudin18.2. Claudin18.2 has been demonstrated to be highly limited in normal tissues and abnormally expressed in various tumor types' main and metastatic foci (e.g., stomach cancer, pancreatic cancer, bile duct cancer). Antibodies can bind to Claudin18.2 on the extracellular membrane, where it plays a role in tumorigenesis and progression.

GemPharmatech has a collection of 39 stomach cancer PDXs some of which express Claudin18.2. These PDXs can be used to evaluate the preclinical efficacy of antibody drugs, ADCs, cell therapy, and other treatments targeting Claudin18.2.

 At present, GemPharmatech' extensive collection possesses 43 cases of PDX tumor samples of Stomach  cancer.


PDX ID         

Histological type       

 Grade                 

Stage                   

 WES    

 RNA-seq     

SC00303

Adenocarcinoma

Low to medium differentiation

N/A

Y

Y

SC00309

Adenocarcinoma

Moderately differentiated

N/A

Y

Y

SC00312

Adenocarcinoma

Poorly differentiated

Ⅲa(pT4aN1M0)

Y

Y

SC00314

N/A

N/A

N/A

Y

Y

SC00332

Adenocarcinoma

Poorly differentiated

N/A

Y

Y

SC00336

Adenocarcinoma

Low to medium differentiation

pT2N0M0 ⅠB

Y

Y

SC00344

Adenocarcinoma

Moderately differentiated

ⅢB(pT4aN0M0)

Y

Y

SC00347

Adenocarcinoma

Moderately differentiated

Ⅳ(T3NXM1)

N/A

Y

SC00352

Adenocarcinoma

Poorly differentiated

T4aN3aM0

Y

N/A


SC00384

Adenocarcinoma

Low to medium differentiation

N/A

Y

Y

SC00400

Adenocarcinoma

Poorly differentiated

Ⅳ

Y

Y

SC00429

N/A


N/A

N/A

Y

Y

SC00436

N/A

N/A

N/A

N/A

Y

SC00439

N/A

N/A

N/A

N/A

Y

SC00485

N/A

N/A

N/A

Y

Y

SC00488

N/A

N/A

N/A

Y

Y

SC00529

Adenocarcinoma


Poorly differentiated

Ⅳ

N/A

N/A

SC00548

N/A


N/A

N/A

N/A

Y

SC00549

Adenocarcinoma

Moderately differentiated

Ⅳ

N/A

Y

SC00558

N/A

Moderately differentiated

Ⅳ

Y

Y

SC00620

N/A

N/A

ⅢA

Y

Y

SC00630

N/A

N/A

N/A

Y

Y

SC00705

Adenocarcinoma

N/A

N/A

Y

Y

SC00708

Adenocarcinoma

N/A

N/A

Y

Y

SC00712

Adenocarcinoma

N/A

N/A

Y

Y

SC00713

Adenocarcinoma

N/A

N/A

Y

Y

SC00714

Adenocarcinoma

N/A

N/A

Y

Y

SC00715

Adenocarcinoma

N/A

N/A

Y

Y

SC00716

Adenocarcinoma

Poorly differentiated

N/A

Y

Y

SC00717

N/A

N/A

N/A

Y

Y

SC00720

N/A

N/A

Ⅲ

Y

Y

SC00726

N/A

N/A

N/A

Y

Y

SC00728

N/A

N/A

N/A

Y

Y

SC00730

N/A

N/A

N/A

Y

Y

SC00733

N/A

N/A

N/A

Y

Y

SC00735

N/A

N/A

N/A

Y

Y

SC00748

N/A

N/A

N/A

Y

Y

SC00752

N/A

N/A

N/A

Y

Y

SC00753

N/A

N/A

N/A

Y

Y

SC00754

N/A

N/A

N/A

Y

Y

SC00760

N/A

N/A

N/A

Y

Y

SC00761

N/

N/A

N/A

Y

Y

SC00763

N/A

N/A

N/A

Y

Y


TALK WITH OUR EXPERTS

GemPharmatechは、お客様のプライバシーを保護し、尊重することをお約束します。お客様の個人情報は、アカウントの管理およびお客様からご要望いただいた製品やサービスの提供に利用いたします。時折、当社の製品やサービスに関する情報や、お客様に興味があるかもしれない他のコンテンツについてご連絡差し上げたいと考えております。お客様にこの目的をご連絡し、ご同意いただける場合は、以下の方法でお客様にどのようにご連絡させていただけるかをお知らせください。

ご希望のコンテンツを提供するために、お客様の個人データを保存および処理する必要があります。この目的でお客様の個人データを保存することにご同意いただける場合は、以下のチェックボックスをクリックしてください。

同意をいつでも撤回する権利があります。購読解除の詳細情報、当社のプライバシーに関する実践、およびお客様のプライバシーを保護し尊重するための取り組みについての詳細については、当社のプライバシーポリシーをご覧ください。